EUVIMEDSkopri EUVIMED
Open access · CC BY 4.0

Characterisation of the novel quinoline RCD405: Relaxant effects on cholinergic and histaminergic tone in human bronchi and small airways

Paola Rogliani iD, Clive Page iD, Francesco Facciolo, Mia Lundblad, Luigino Calzetta iD

British Journal of Pharmacology · 2025

DOI: 10.1111/bph.70073 ↗

At a glance

Journal article in British Journal of Pharmacology, 2025. Written by Paola Rogliani and 4 co-authors. Institution: Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome 'Tor Vergata', Rome, Italy. Major MEDLINE topics: Bronchi, Quinolines, Bronchodilator Agents, Muscle, Smooth. 55 references. The full text is freely available (open access, CC BY 4.0). Funded by: Arcede Pharma AB (Medicon Village SE-223 81 Lund, Sweden).

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background and Purpose Increased contractility of human airway smooth muscle (hASM) is a hallmark of asthma and chronic obstructive pulmonary disease (COPD). Developing new classes of bronchodilators has proved to be challenging because of efficacy and safety concerns. Quinolines hold potential therapeutic applications for the treatment of respiratory disorders. Experimental Approach Relaxant effects of the novel quinoline RCD405 were investigated on contractile responses of hASM to carbachol, histamine and electrical field stimulation (EFS). The role of the non‐adrenergic non‐cholinergic (NANC) system was assessed using the inducible NO synthase inhibitor aminoguanidine and the TRPV1 agonist capsaicin. Key Results In medium bronchi, RCD405 elicited a maximum relaxant effect ( E max ) of 92 ± 4% with a half‐maximal effective concentration (EC 50 ) of 45.71 μM for carbachol, and an E max of 96 ± 1% with a EC 50 of 12 μM for histamine. In small airways, RCD405 demonstrated significant relaxant responses, with an E max of 54 ± 7% (EC 50 17 μM) for carbachol and 90 ± 6% (EC 50 20 μM) for histamine. RCD405 reduced contractility in response to EFS, with E max values of 63 ± 10% at 25 Hz and 79 ± 9% at 50 Hz in medium bronchi. The NANC system did not affect the bronchorelaxation induced by RCD405. Conclusions and Implications RCD405 showed significant potential as a novel bronchodilator drug for the treatment of asthma and COPD through its ability to induce relaxation of hASM. These findings suggest that further investigation of RCD405 is warranted as a possible novel treatment of chronic respiratory disorders.

Subjects

MeSH terms (MEDLINE)

BronchiQuinolinesBronchodilator AgentsMuscle, SmoothHumansHistamineMaleCarbacholFemaleMiddle AgedMuscle RelaxationMuscle ContractionIn Vitro TechniquesElectric StimulationAdultAgedDose-Response Relationship, DrugTRPV Cation Channels

Author keywords

COPDRCD405asthmabronchodilatorhuman airway smooth muscle

Substances

HistamineQuinolinesBronchodilator AgentsCarbacholTRPV Cation Channels

Authors and institutions

  • Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome 'Tor Vergata', Rome, Italy.
  • Pulmonary Pharmacology Unit, Institute of Pharmaceutical Science, King's College London, London, UK.
  • Thoracic Surgery Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • R&D Department, Arcede Pharma AB, Medicon Village, Lund, Sweden.
  • Respiratory Disease and Lung Function Unit, Department of Medicine and Surgery, University of Parma, Parma, Italy.

ORCID profiles: Paola Rogliani, Clive Page, Luigino Calzetta

Funding

  • Arcede Pharma AB (Medicon Village SE-223 81 Lund, Sweden)

Cite

APA

Rogliani, P., Page, C., Facciolo, F., Lundblad, M., & Calzetta, L. (2025). Characterisation of the novel quinoline RCD405: Relaxant effects on cholinergic and histaminergic tone in human bronchi and small airways. British Journal of Pharmacology. https://doi.org/10.1111/bph.70073

Vancouver

Rogliani P, Page C, Facciolo F, Lundblad M, Calzetta L. Characterisation of the novel quinoline RCD405: Relaxant effects on cholinergic and histaminergic tone in human bronchi and small airways. British Journal of Pharmacology. 2025. doi:10.1111/bph.70073

BibTeX
@article{Rogliani2025,
  author = {Rogliani, Paola and Page, Clive and Facciolo, Francesco and Lundblad, Mia and Calzetta, Luigino},
  title = {Characterisation of the novel quinoline RCD405: Relaxant effects on cholinergic and histaminergic tone in human bronchi and small airways},
  journal = {British Journal of Pharmacology},
  year = {2025},
  doi = {10.1111/bph.70073}
}
Start for free →